Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II AGO trial of Myocet with or without gemcitabine in platinum-refractory/resistant ovarian, fallopian tube, or primary peritoneal cancer
2008-008746-20Phase 2Terminated
- Sponsor
- AGO Austria
- Start
- Feb 2009
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in epithelial ovarian cancer (EOC), fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) comparing Myocet monotherapy with Myocet + Gemzar combination (2 arms). Primary endpoint: Objective response rate. Started Feb 2009; status: terminated.
02
Drugs
doxorubicingemcitabine
03
Conditions
epithelial ovarian cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2008-008746-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-008746-20.